StockData
Vaxart, Inc. logo

Vaxart, Inc. (VXRT) stock

VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/30
$0.48+0.02 (+5.04%)

Close on Oct 19, 2026Market cap $115.15MP/E 3.2Yield –

Vaxart gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Vaxart's gross profit for the twelve months ending Jun 30, 2016 was -$25.20M, down 220.0% year over year. For fiscal 2015 it was $21.00M, up 19.3% from the year before. The highest annual figure on record is $21.00M in fiscal 2015.

Annual gross profit

PeriodPeriod endValueChange
FY2015Jun 30, 2015$21.00M+19.3%
FY2014Jun 30, 2014$17.60M+26.6%
FY2013Jun 30, 2013$13.90M+32.4%
FY2012Jun 30, 2012$10.50M+23.5%
FY2009Dec 26, 2009$8.50M–

Quarterly gross profit

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2016CQ2 2016Jun 30, 2016-$6.80M–
Q3 FY2016CQ1 2016Mar 31, 2016-$5.20M-572.7%
Q2 FY2016CQ4 2015Dec 31, 2015-$6.50M–
Q1 FY2016CQ3 2015Sep 30, 2015-$6.70M–
Q4 FY2015CQ2 2015Jun 30, 2015-$20.00M–
Q3 FY2015CQ1 2015Mar 31, 2015$1.10M–

More Vaxart figures

See a number that looks wrong?